Oncodetect MRD
Tumor-informed ctDNA molecular residual disease test used across solid tumors; current commercial configuration tracks up to 200 tumor-specific variants.
- Developer
- Exact Sciences
- Intended use
- Mrd
- Cancer scope
- Colorectal cancer
- Specimen
- FFPE tumor tissue, Peripheral whole blood
- Molecular modality
- DNA mutation
- Current version
- Current Oncodetect up-to-200-variant tumor-informed MRD configuration
- Evidence context
- 2 structured studies · 4 indexed performance results · 3 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.